What is the precise date of semaglutide's patent expiry?

What happens when semaglutide's patent expires?

Semaglutide, a medication used to treat type 2 diabetes and obesity, is a medication developed by Novo Nordisk. As of now, we could not find a specific patent file number associated with Semaglutide. Novo Nordisk's patent for semaglutide has been subject to various patent filings; however, according to a recent patent search on DrugPatentWatch.com [1], the earliest known expiration date for a US semaglutide patent is September 14, 2032 (Patent No. US 10,855,135 B2). Please note that patent filings and expiration dates might change, so these details are subject to future updates.

Can biosimilars enter before patent expiry?

Regulatory processes for biosimilar entry in the US, such as the BLA (Biologic License Application), are ongoing, and timelines for each product vary. Even when the original patent expires, regulatory hurdles and litigation might delay the market entry of biosimilars.

Will the patent expiry change the market dynamics for semaglutide?

As the patent for semaglutide expires, several biosimilars may be approved to market and distribute their version of semaglutide. Potential competitors in this market could lead to a decrease in price as well as an increasing number of available treatment options.

What should patients know about patent expiry for semaglutide?

Patients should follow up with their healthcare provider for guidance on switching to a generic version of semaglutide, if available. The generic or biosimilar version will not have the same brand-name price, but patients should ensure that their treatment and dosing remain under the guidance of their medical provider.

Sources:
[1] DrugPatentWatch.com. Novo Nordisk: Patents & Exclusivities. https://www.drugpatentwatch.com/drug.php?genericname=semaglutide&market=usa&searchtype=drug